Change over period: —
NSE · NURECA
NURECA
-17.5% from the 52-week high · +46.2% above the low
Nureca Ltd. design and manufactures health monitoring devices. The company is headquartered in Mumbai, Maharashtra and currently employs 102 full-time employees. The company went IPO on 2021-02-25. The main products/services that the Company manufactures include chronic disease products, orthopedic products, mother and child products, nutrition supplements, lifestyle products, and connected devices. Its chronic disease products include nebulizers, BP monitors, finger pulse oximeters, glucose meters and thermometers. Its orthopedic products include wheelchairs, walkers, lumbar and tailbone supports and physiotherapy electric massagers. Its mother and babycare products include baby feeding, carry cots, baby skincare, nebulizers and bottle warmers and steamers. Its nutrition supplements include supplements and weight management products. Its lifestyle products include humidifiers and steamers, personal scales, massagers, fitness tracking, and dental and personal care. The firm's products are offered through its brands, such as Dr Trust, Dr Physio, and Trumom.
The short version. NURECA reported revenue of ₹59 crore for Sep 2026, up 55.3% from a year earlier. Net profit was ₹4 crore (up 0.0% year on year). Return on equity was 1.1% in Mar 2026. Promoter holding was 70.68% in Sep 2026, up 6.62 points over 8 quarters.
1 · The price
How has the stock traded?
NURECA trades 17.5% below its 52-week high and 46.2% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹59 cr.
Sep 2026 net profit of ₹4 cr.
2.7 pts lower than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 59 | 40 | 35 | 40 | 38 | 34 | 32 | 26 |
| Net profit | 4 | 3 | -6 | 4 | 4 | 1 | 2 | -3 |
| Net margin % | 6.9 | 7.6 | -17.2 | 9.4 | 9.6 | 2.4 | 7.8 | -10.6 |
| EPS (₹) | 4.25 | 3.22 | -6.38 | 3.73 | 3.63 | 0.81 | 2.47 | -2.8 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Revenue | 147 | 110 | 92 | 111 | 256 | 213 |
| Net profit | 2 | 1 | -2 | -8 | 45 | 46 |
| Net margin % | 1.4 | 0.8 | -2.0 | -7.4 | 17.6 | 21.7 |
| EPS (₹) | 2.18 | 0.85 | -1.79 | -8.25 | 44.96 | 46.37 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 1.1% in Mar 2026; debt to equity is 0.00.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 1.1 | 0.4 | -0.9 | -4.2 |
| Return on capital % | 3.4 | 1.3 | -1.1 | -5.2 |
| EBITDA margin % | 5.3 | 4.0 | 0.3 | -6.7 |
| Net margin % | 1.3 | 0.7 | -1.8 | -7.0 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 9.4% | -6.4% |
| Profit CAGR | — | -46.2% |
4 · The owners
Who holds it, and are they adding?
Up 6.62 pts over 8 quarters.
Down 0.14 pts over 8 quarters.
Up 0.2 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 64.06 | 64.3 | 64.33 | 64.97 | 64.97 | 68.09 | 68.09 | 70.68 | +6.62 |
| FII | 0.36 | 1.07 | 0.07 | 0.07 | 0.08 | 0.28 | 0.11 | 0.22 | -0.14 |
| DII | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.24 | 0.24 | 0.24 | +0.2 |
| Public | 35.54 | 34.59 | 35.56 | 34.92 | 34.91 | 31.39 | 31.57 | 28.86 | -6.68 |
Mutual fund holdings · Oct 2026
0 schemes hold this stock
0 the month before.
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for NURECA are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Healthcare Equipment & Supplies stocks
Quick answers
Common questions about NURECA
What is the NURECA share price?
NURECA (NURECA) last closed at ₹299.90, down 0.81% on the day. Its 52-week range is ₹206.75 to ₹366.60.
What is the market cap of NURECA?
NURECA has a market capitalisation of about ₹282 crore. Its price-to-earnings ratio is 51.2.
How are NURECA's latest results?
NURECA reported revenue of ₹59 crore for Sep 2026, up 55.3% from a year earlier. Net profit was ₹4 crore (up 0.0% year on year). Return on equity was 1.1% in Mar 2026. Promoter holding was 70.68% in Sep 2026, up 6.62 points over 8 quarters.
Who owns NURECA?
As of Sep 2026, shareholding was: Promoter 70.68%, FII 0.22%, DII 0.24%, Public 28.86%.
How many mutual funds hold NURECA?
0 mutual fund schemes held NURECA in October 2026. That compares with 0 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 24 Feb 2022 · Interim Dividend - Rs. 3
- 21 Sep 2021 · Dividend - Rs. 2
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.